PREDICTIVE VALUE OF CARDIAC CACHEXIA IN CHRONIC HEART FAILURE
https://doi.org/10.15829/1728-8800-2016-4-80-83
Abstract
Regardless current achievements of medicine, chronic heart failure (CHF) is still the leading cause of cardiovascular morbidity and mortality. A special cohort in CHF mortality are patients with progressive body mass loss. Recently the assessment of cachexia is restricted only with the tests revealing present atrophy, but not to predict it. Therefore, of the most significant investigation directions is search for reliable biomarkers of early diagnostics and efficacy assessment. The article focuses on the main biomarkers having potential prediction value and recommended for cardiac cachexia assessment.
About the Authors
E. S. Drobysheva
N. N. Burdenko Voronezh State Medical University, Voronezh
Russian Federation
Russian Federation
R. E. Tokmachev
N. N. Burdenko Voronezh State Medical University, Voronezh
Russian Federation
Russian Federation
A. V. Budnevsky
N. N. Burdenko Voronezh State Medical University, Voronezh
Russian Federation
Russian Federation
A. Ya. Kravchenko
N. N. Burdenko Voronezh State Medical University, Voronezh
Russian Federation
Russian Federation
References
1. Diagnostics and treatment of chronic heart failure. In. National clinical guidelines 4th ed. Ed. by RG Oganov. Moscow: Silicea-Polygraf, 2011: 203-296. Russian (Диагностика и лечение хронической сердечной недостаточности. В кн: Национальные клинические рекомендации. 4-е издание. Под ред. Р.Г. Оганова. М.: Силицея-Полиграф, 2011: 203-296).
2. Belenkov YuN, Mareev VYu, Ageev FT et al. True prevalence of CHF in the European part of the Russian Federation (the EPOCH study, hospital stage). Heart failure 2011; 12(2): 63-68. Russian (Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. и др. Истинная распространенность ХСН в Европейской части Российской Федерации (исследование ЭПОХА, госпитальный этап). Сердечная недостаточность 2011; 12(2): 63-68).
3. Lotfullina ASh, Kamalov GM, Galyavich AS. Analysis of mortality in patients with chronic heart failure. Cardiovascular therapy and prevention 2005; 4(4): 193. Russian (Лотфуллина А.Ш., Камалов Г.М., Галявич А.С. Анализ смертности больных с хронической сердечной недостаточностью. Кардиоваскулярная терапия и профилактика 2005; 4(4): 193).
4. Arutyunov GP. Cachexia in patients with chronic heart failure. What is the scale of the problem? What do we know and what do we do? Heart failure 2001; 2(3): 32. Russian. (Арутюнов Г.П. Кахексия у больных с хронической сердечной недостаточностью. Каков масштаб проблемы? Что мы знаем и что нам делать? Сердечная недостаточность 2001; 2(3): 32).
5. Evans WJ, Morley JE, Argiles J et al. Cachexia: A new definition. Clin. Nutr. 2008; 7: 793–799.
6. Egorova EN, Kuzmina M, Mazur VV et al. Dynamics of cytokine- and endotoxemia in the treatment of chronic heart failure. Cardiovascular therapy and prevention 2009; 8(6): 126. Russian (Eгорова Е.Н., Кузьмина М., Мазур В.В. и др. Динамика цитокин- и эндотоксинемии при лечении хронической сердечной недостаточности. Кардиоваскулярная терапия и профилактика 2009; 8(6): 126).
7. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int. J. Cardiol. 2002; 85: 51–66.
8. Palus S, von Haehling S, Springer, J. Muscle wasting: An overview of recent developments in basic research. J. Cachexia Sarcopenia Muscle 2014; 5: 193–198.
9. Heymsfield SB, Adamek M, Gonzalez MC et al. Assessing skeletal muscle mass: Historical overview and state of the art. J. Cachexia Sarcopenia Muscle 2014; 5: 9–18.
10. Apostolakis S, Vogiatzi K, Krambovitis E et al. IL-1 cytokines in cardiovascular disease: diagnostic, prognostic and therapeutic implications. Cardiovascular & hematological agents in medicinal chemistry 2008; 6(2): 150–8.
11. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin. Physiological reviews 2008; 88(4): 1379–406.
12. Wu JT, Kral JG. Ghrelin: Integrative neuroendocrine peptide in health and disease. Ann. Surg. 2004; 239: 464–474.
13. Attanasio P, Anker SD, Doehner W et al. Hormonal consequences and prognosis of chronic heart failure. Curr. Opin. Endocrinol. Diabetes Obes. 2011; 18: 224–230.
14. Strasser F. Clinical application of ghrelin. Curr. Pharm. Des. 2012; 18: 4800–4812.
15. Szabó T, Scherbakov N, Sandek A et al. Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr. Metab. Cardiovasc. Dis. 2014; 24: 50–56.
16. Skibchik VA, Skibchik JaV. The problem of leptinemia in cardiovascular diseases. Ukraїns'kij medichnij chasopis 2007; 11/12: 45-51. Russian (Скибчик В.А., Скибчик Я.В. Проблема лептинемии при сердечно-сосудистых заболеваниях. Український медичний часопис 2007; 11/12: 45-51.)
17. McEntegart MB, Awede B, Petrie MC. et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: Relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur. Heart J. 2007; 28: 829–835.
18. Loncar G, Bozic B, von Haehling S et al. Association of adiponectin with peripheral muscle status in elderly patients with heart failure. Eur. J. Intern. Med. 2013; 24: 818–823.
19. Ebner N, Steinbeck L, Doehner W et al. Highlights from the 7th cachexia conference: Muscle wasting pathophysiological detection and novel treatment strategies. J. Cachexia Sarcopenia Muscle 2014; 5: 27–34. Int. J. Mol. Sci. 2014; 15: 23896
20. Steinbeck L, Ebner N, Valentova M et al. C-terminal agrin fragment as a novel diagnostic marker for muscle wasting in patients with chronic heart failure: Results from the studies investigating co-morbidities aggravating heart failure. J. Cachexia Sarcopenia Muscle 2014; 5: 1–32.
21. Lerner L, Guillory B, Chen J et al. Growth differentiating factor-15 (GDF-15) induces anorexia and cachexia in mice: A novel pathway for cachexia. J. Cachexia Sarcopenia Muscle 2013; 4: 295–343.
22. Martins T, Vitorino R, Amado F et al. Biomarkers for cardiac cachexia: Reality or utopia. Clin. Chim. Acta 2014; 436: 323–328.
23. Fragala MS, Jajtner AR, Beyer KS et al. Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults. J. Cachexia Sarcopenia Muscle 2014; 5: 139–148.
24. Bhasin S, He EJ, Kawakubo M et al. N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone. J. Clin. Endocrinol. Metab. 2009; 94: 4224–4233.
25. Nedergaard A, Sun S, Karsdal MA et al. Type VI collagen turnover-related peptides-novel serological biomarkers of muscle mass and anabolic response to loading in young men. J. Cachexia Sarcopenia Muscle 2013; 4: 267–275.
26. Nedergaard A, Karsdal MA, Sun S et al. Serological muscle loss biomarkers: An overview of current concepts and future possibilities. J. Cachexia Sarcopenia Muscle 2013; 4: 1–17.
27. Scott IC, Tomlinson W, Walding A et al. Large-scale isolation of human skeletal muscle satellite cells from post-mortem tissue and development of quantitative assays to evaluate modulators of myogenesis. J. Cachexia Sarcopenia Muscle 2013; 4: 157–169.
28. Loncar G, Fulster S, von Haehling S et al. Metabolism and the heart: An overview of muscle, fat, and bone metabolism in heart failure. Int. J. Cardiol. 2013; 162 :77–85.
29. Stimpson SA, Leonard MS, Clifton L.G. et al. Longitudinal changes in total body creatine pool size and skeletal muscle mass using the D-creatine dilution method. J. Cachexia Sarcopenia Muscle 2013; 4: 217–223.
Review
For citations:
Drobysheva E.S., Tokmachev R.E., Budnevsky A.V., Kravchenko A.Ya. PREDICTIVE VALUE OF CARDIAC CACHEXIA IN CHRONIC HEART FAILURE. Cardiovascular Therapy and Prevention. 2016;15(4):80-83. (In Russ.) https://doi.org/10.15829/1728-8800-2016-4-80-83
Views:
1329
Email this article 
